Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Colin Smith
  • Colin Smith

Craneware Group | FY25 update – Confident in double digit growth

Craneware has released a very positive update ahead of its FY25 results, highlighting revenue growth of 9% YoY to US$205.7m with even stronger growth of 12% in adjusted EBITDA to over US$65m. The company ended the period with net cash of US$28.2m. Moreover, Annual Recurring Revenue increased 7% to US$184m (2% YoY growth in FY24) and Net Revenue Retention was even more impressive, increasing to 107% (FY24 98%). All of which confirms that the company is really beginning to press the accelerator on...

Colin Smith
  • Colin Smith

TheraCryf (TCF) | AGM updates on OX-1 and SFX-01 programmes

TheraCryf held its AGM yesterday at which management emphasised its focus on brain disorders and specifically on advancing the Orexin (Ox-1) programme acquired in the Chronos transaction to clinical stage readiness by the end of calendar 2026, for which the company is now fully funded. The legacy synthetic Sulforaphane molecule (SFX-01) continues to be progressed in third-party funded programmes, most notably in the potential treatment for the brain cancer Glioblastoma at the Erasmus Medical Cen...

Colin Smith
  • Colin Smith

Galliford Try | FY25 Trading Update - Results beat expected, again

Galliford Try's results continue to affirm the strength of its strategy, market positioning, execution, and risk management. After a strong performance for 1HFY25, full-year guidance to June is again for a beat to expectations with revenue and adjusted profit before tax expected to slightly exceed the top end of market forecasts, currently standing at £1,885.6m and £41.6m, respectively. That is despite a 14.4% hike in the consensus forecast for adjusted profit before tax since January. The comp...

Sarah Godfrey
  • Sarah Godfrey

Schroder AsiaPacific Fund | Dedicated followers of quality at reasonab...

In an asset class that is perhaps more susceptible to ‘fashion' than others, with hot-money investors chasing the next big thing, SDP is reassuringly sensible in its focus on finding quality, well-governed and return-generative Asia-Pacific companies at valuations that leave a margin of safety to support long-term growth. The managers are not afraid to back their best ideas – the top 10 stocks (of c 50) account for more than 45% of the portfolio – but they also have a large, dedicated and locall...

Sarah Godfrey
  • Sarah Godfrey

JP Morgan Emerging Markets | Long-established fund with focus on quali...

While it may not quite be the oldest of the emerging markets investment trusts (Fidelity Emerging Markets [formerly Genesis Emerging Markets] and Templeton Emerging Markets were both launched in 1989), JPMorgan Emerging Markets (JMG) does have the longest record of consistent management, with Austin Forey having run the portfolio on broadly the same lines for more than 30 years. J.P. Morgan Asset Management (JPMAM) has a wealth of analyst resources covering not just the well-known EM companies, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch